| Previous Section | Index | Home Page |
4 Mar 2005 : Column 1459W—continued
Cruse Bereavement Care
Lady Hermon:
To ask the Secretary of State for Health what funding was made available by his Department to Cruse Bereavement Care in each of the
4 Mar 2005 : Column 1460W
past five years for which figures are available; and what plans he has to increase the funding. [219768]
Ms Rosie Winterton: The Department has provided Cruse Bereavement Care with funding over a number of years under the Section 64 General Scheme. Details of awards over the last five years are shown in the table.
The Department has no current plans to increase funding to Cruse. However Cruse, in common with other voluntary and community sector organisations, is able to apply for funding from the Department's Section 64 Scheme and any other Government funding streams.
DEHP Plasticiser
Mr. Dhanda: To ask the Secretary of State for Health if he will make a statement on the resolution by the European Parliament to restrict DEHP plasticiser in medical devices. [218986]
Ms Rosie Winterton: The Government are aware of the European Parliament Resolution on the European Environment and Health Action Plan 2004–2010, which refers to the restriction of Di (2-ethylhexyl) phthalate (DEHP) in medical devices except where such a restriction would have a negative impact on medical treatment. Medical devices are placed on the European Market in accordance with the provisions of the Medical Devices Directive. In meeting the relevant essential safety requirements, manufacturers must make an assessment that any risks are outweighed by the clinical benefits and that evidence of such benefits are provided.
The Medicines and Healthcare products Regulatory Agency (MHRA) which is the body in the United Kingdom with oversight for the Medical Devices Directive, has ensured that appropriate manufacturer's representative bodies are fully aware of the implications of the directive as they apply to DEHP-containing medical devices.
The Agency is also aware of, and is encouraging, manufacturers' efforts to find alternative material to phthalates, looking at ways of limiting exposure to DEHP and gaining a better understanding of DEHP toxicity
Dentistry
Sir Paul Beresford: To ask the Secretary of State for Health pursuant to the answer of 10 February 2005, Official Report, column 1688W, on dentistry, how many dentists returned to NHS dentistry from a career break between (a) April 2001 to March 2002, (b) April 2002 to March 2003 and (c) April 2003 to March 2004. [219380]
Ms Rosie Winterton [holding answer 1 March 2005]: 46 dentists returned to national health service dentistry and were members of the "Keeping In Touch" scheme between April 2003 and March 2004. Data is not available for the previous two years.
Sir Paul Beresford: To ask the Secretary of State for Health pursuant to the answer of 10 February 2005, Official Report, column 1688W, on dentistry, and the answer to my hon. Friend the Member for Westbury (Dr. Murrison) on 9 February 2005, Official Report, column 1620W, on the "Keeping in Touch" scheme, what information he collects on the number of whole-time equivalent dentists being recruited as a result of the "Keeping in Touch" scheme. [219382]
Ms Rosie Winterton [holding answer 1 March 2005]: The Department collects information from the retaining and returning adviser in the dental postgraduate deanery on the dentist's date of return to work, the primary care trust where the dentist is working and the number of sessions worked.
Mr. Rosindell: To ask the Secretary of State for Health if he will make a statement on dental registration rates. [217609]
Ms Rosie Winterton: I refer the hon. Member to the reply I gave to the hon. Member for Meriden (Mrs. Spelman) on 22 February 2005, Official Report, column 486W. We are undertaking the most far-reaching reforms to national health service dentistry since 1948, in order to make NHS dentistry more attractive to dentists.
Drug Rehabilitation
Dr. Cable: To ask the Secretary of State for Health what the budget is for drug rehabilitation in 2004–05; what allocation he has made up to 2007–08; and if he will make a statement. [216744]
Miss Melanie Johnson:
The pooled drug treatment budget for 2004–05 and the allocated funding up until 2007–08 is shown in the table.
4 Mar 2005 : Column 1461W
| Amount (£ million) | |
|---|---|
| 2004–05 | 253.4 |
| 2005–06 | 299.4 |
| 2006–07 | 423.8 |
| 2007–08 | 478.4 |
It is estimated that an additional £200 million mainstream funding is being spent on drug treatment in 2004–05, but we are not able to estimate the mainstream spend in future years.
These figures incorporate all six treatment modalities. These are day care; general practitioner prescribing; specialist prescribing; residential rehabilitation; in-patient detoxification and structured counselling. We do not have specific spend figures by individual treatment type.
Dr. Iddon: To ask the Secretary of State for Health pursuant to the statement by the Parliamentary Under-Secretary of State for the Home Department in the Standing Committee on the Drugs Bill on 3 February 2005, fifth sitting, Official Report, column 155, what progress has been made by (a) his Department and (b) the national treatment agency in advising (i) general practitioners and (ii) other prescribers to consider using opiate substitutes other than methadone. [217073]
Miss Melanie Johnson: A decision to use buprenorphine or opiates other than methadone for opiate substitution treatment requires knowledge and understanding of the use of these drugs in the management of addiction, as well as their limitations. Such treatment would normally be initiated by a specialist or a general practitioner with additional competence in this area of practice.
To support effective prescribing of a range of opiates, the Department has issued the clinical guidelines, "Drug misuse and dependence—guidelines on clinical management" (1999). The Department issued additional guidance on the availability of buprenorphine by instalment dispensing in 2001. In addition, the Department has funded the training of 800 GPs in a range of substitute opiates through funding of the Royal College of General Practitioners certificate course between 2002 and 2005.
The national treatment agency (NTA) for substance misuse has produced clinical guidance, "Prescribing services for drug misusers" (Research into practice briefing No. 2, January 2003), that includes a review of the evidence base concerning a range of pharmacological treatments for drug misusers, including alternative opiate substitute drugs. Further clinical guidance, "Injectable heroin (and injectable methadone)—potential roles in drug treatment" (May 2003), also gives advice on alternatives to methadone substitution therapy.
East Elmbridge and Mid Surrey PCT
Chris Grayling: To ask the Secretary of State for Health what proportion of spending on acute services by the East Elmbridge and Mid Surrey primary care trust was spent at (a) Epsom and St. Helier, (b) Guildford, (c) Kingston, (d) East Surrey and (e) St. Peter's hospitals in each of the last three years. [219407]
4 Mar 2005 : Column 1462W
Ms Rosie Winterton: The information requested is not collected centrally.
Chris Grayling: To ask the Secretary of State for Health how many people have become obese in the East Elmbridge and Mid Surrey primary care trust area in each of the past three years. [219447]
Ms Rosie Winterton: The information requested is not collected centrally.
| Next Section | Index | Home Page |